Insider Selling: Inogen, Inc (NASDAQ:INGN) EVP Sells 6,667 Shares of Stock
Inogen, Inc (NASDAQ:INGN) EVP Alison Bauerlein sold 6,667 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $92.64, for a total transaction of $617,630.88. Following the completion of the transaction, the executive vice president now owns 15,000 shares in the company, valued at approximately $1,389,600. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Inogen, Inc (INGN) traded up 0.10% during midday trading on Friday, hitting $91.52. 154,951 shares of the stock traded hands. The company has a 50-day moving average of $94.61 and a 200-day moving average of $82.03. Inogen, Inc has a 1-year low of $50.24 and a 1-year high of $98.33. The stock has a market cap of $1.90 billion, a PE ratio of 79.44 and a beta of 1.01.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million during the quarter, compared to the consensus estimate of $59.99 million. During the same period in the prior year, the firm earned $0.25 EPS. The business’s revenue was up 17.4% on a year-over-year basis. On average, equities analysts expect that Inogen, Inc will post $1.21 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Inogen, Inc (NASDAQ:INGN) EVP Sells 6,667 Shares of Stock” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/insider-selling-inogen-inc-nasdaqingn-evp-sells-6667-shares-of-stock/1475464.html.
A number of hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. bought a new stake in shares of Inogen during the first quarter worth $109,000. Schroder Investment Management Group bought a new stake in shares of Inogen during the second quarter worth $132,000. Victory Capital Management Inc. increased its stake in shares of Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after buying an additional 459 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the period.
A number of equities analysts have commented on INGN shares. Needham & Company LLC reiterated a “buy” rating and issued a $96.00 price objective on shares of Inogen in a report on Wednesday, May 10th. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Stifel Nicolaus boosted their price objective on shares of Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a report on Wednesday, May 10th. Finally, Sidoti initiated coverage on shares of Inogen in a research report on Tuesday, April 18th. They issued a “neutral” rating and a $79.00 target price for the company. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $91.60.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.